News
Global pharmaceutical giant Eli Lilly & Co. is considering a $5.9 billion plant in northeast Houston, a potential economic ...
As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...
Pharma giant Eli Lilly is planning a $5.9 billion investment for a massive pharmaceutical manufacturing facility in McCord ...
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish ...
With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...
Pharmaceutical manufacturing giant Eli Lilly and Co. is exploring potential economic incentives for a $5.9B biomanufacturing ...
Drugmaker Eli Lilly and Company has hired Sandy Rodriguez as SVP and chief communications officer, effective on June 9. Rodriguez will report to Jennifer Oleksiw, SVP and global chief customer officer ...
The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...
Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...
Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, ...
Lilly employees log over 1 million hours of volunteer time during global service initiative, benefiting communities in Indiana.
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results